Published in J Urol on September 01, 2004
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Racial variation in the quality of surgical care for bladder cancer. Cancer (2013) 1.45
Performance of partial cystectomy in the United States from 2001 to 2010: trends and comparative outcomes. Can J Urol (2014) 1.39
Bladder cancer in the elderly. Urol Oncol (2009) 1.26
Laparoscopic partial cystectomy for urachal and bladder cancer. Clinics (Sao Paulo) (2008) 1.07
Initial experience with robotic-assisted laparoscopic partial cystectomy in urachal diseases. Korean J Urol (2010) 0.98
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol (2011) 0.87
Function-preserving surgery for urologic cancer. Int J Clin Oncol (2006) 0.82
Impact of treatment delay in patients with bladder cancer managed with partial cystectomy in Quebec: a population-based study. Can Urol Assoc J (2009) 0.82
Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer (2014) 0.81
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl (2016) 0.78
Deceptive muscle invasive bladder cancer recurrence with benign biopsy foci after bladder sparing treatment. Medicine (Baltimore) (2015) 0.77
Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. Int Sch Res Notices (2014) 0.75
Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery? Urol Clin North Am (2015) 0.75
Where are we with bladder preservation for muscle-invasive bladder cancer in 2017? Indian J Urol (2017) 0.75
Everything old is new again. J Urol (2004) 0.75
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer (2015) 0.75
Cystoscopic-assisted partial cystectomy: description of technique and results. Res Rep Urol (2014) 0.75
Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. World J Urol (2017) 0.75
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol (2017) 0.75
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol (2007) 5.03
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol (2009) 4.27
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol (2013) 2.78
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol (2006) 2.70
Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology (2002) 2.63
An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol (2004) 2.53
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Adult spermatic cord sarcomas: management and results. Ann Surg Oncol (2003) 2.52
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol (2002) 2.39
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters. Eur Urol (2011) 2.36
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol (2010) 2.32
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol (2006) 2.30
Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol (2010) 2.27
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Mini-flank supra-11th rib incision for open partial or radical nephrectomy. BJU Int (2006) 2.19
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int (2010) 2.10
Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol (2004) 2.09
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int (2006) 2.00
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol (2009) 1.98
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol (2003) 1.95
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol (2002) 1.88
Solid renal cortical tumors: differentiation with CT. Radiology (2007) 1.87
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol (2007) 1.87
Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol (2007) 1.84
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol (2002) 1.82
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol (2011) 1.81
Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol (2004) 1.81
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79
A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int (2006) 1.79
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? J Urol (2010) 1.78
Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol (2009) 1.78
A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int (2008) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology (2012) 1.75
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer (2006) 1.75
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol (2011) 1.71
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol (2011) 1.64
Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol (2003) 1.63
Trends in renal tumor surgery delivery within the United States. Cancer (2010) 1.62